We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: venous thromboembolism
MedXY News
EnglishTag

venous thromboembolism

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Enhancing Venous Thromboembolism Prevention Through Patient-Centered Nurse and Patient Education in Community Hospitals
Internal Medicinevenous thromboembolism

Enhancing Venous Thromboembolism Prevention Through Patient-Centered Nurse and Patient Education in Community Hospitals

By MedXY|Oct 9, 2025

A nurse-driven, patient-centered education bundle significantly reduced missed doses of venous thromboembolism prophylaxis in a community hospital, demonstrating scalable improvements in prophylaxis adherence beyond academic centers.

Optimizing Extended Apixaban Therapy for Venous Thromboembolism: Insights from Recent Randomized Trials
CardiologyanticoagulationApixaban

Optimizing Extended Apixaban Therapy for Venous Thromboembolism: Insights from Recent Randomized Trials

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
By MedXY|Oct 9, 2025

Extended low-dose apixaban significantly reduces recurrent venous thromboembolism (VTE) in patients with provoked VTE and enduring risk factors, with minimal major bleeding. Reduced-dose apixaban for cancer-associated VTE is equally effecti

Extended Apixaban Therapy Reduces Recurrent VTE Risk in Patients with Provoked Events and Enduring Risk Factors
CardiologyApixabanvenous thromboembolism

Extended Apixaban Therapy Reduces Recurrent VTE Risk in Patients with Provoked Events and Enduring Risk Factors

By MedXY|Oct 9, 2025

A randomized trial demonstrates that low-dose apixaban for 12 months significantly lowers symptomatic recurrent VTE risk after provoked events with enduring risk factors, with minimal major bleeding.

Evaluating Low-Dose Aspirin for Postpartum Venous Thromboembolism Prevention: Insights from the Pilot PARTUM Trial
Clinical Updateslow-dose aspirinrandomized trial

Evaluating Low-Dose Aspirin for Postpartum Venous Thromboembolism Prevention: Insights from the Pilot PARTUM Trial

By MedXY|Oct 8, 2025

The pilot PARTUM trial demonstrates the feasibility of a large-scale multi-national randomized study assessing low-dose aspirin versus placebo for postpartum venous thromboembolism prevention in moderate-risk individuals, supporting further

Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Insights from a Large French Observational Study
Clinical UpdatesHemolytic AnemiaMycoplasma pneumoniae

Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Insights from a Large French Observational Study

By MedXY|Oct 5, 2025

A national French study reveals that cold agglutinin syndrome (CAS) develops about 10 days after Mycoplasma pneumoniae infection onset, often requiring ICU care and transfusions, with a generally favorable prognosis despite frequent venous

Venous Thromboembolism in Newly Diagnosed Lymphoma Patients: Insights from a Real-World Vietnamese Cohort
Hematology-OncologyD-dimerLymphoma

Venous Thromboembolism in Newly Diagnosed Lymphoma Patients: Insights from a Real-World Vietnamese Cohort

By MedXY|Oct 5, 2025

An 8.3% incidence of VTE was observed in newly diagnosed lymphoma patients in Vietnam, with pretreatment elevated D-dimer and cardiovascular comorbidities as key risk factors, emphasizing the need for tailored thromboprophylaxis.

Evaluating the Adjuvant Role of Low-Dose Aspirin in Cancer-Associated Venous Thromboembolism: Efficacy, Safety, and Clinical Implications
OncologyanticoagulationAspirin

Evaluating the Adjuvant Role of Low-Dose Aspirin in Cancer-Associated Venous Thromboembolism: Efficacy, Safety, and Clinical Implications

By MedXY|Oct 4, 2025

Low-dose aspirin added to anticoagulation for cancer-associated VTE reduces recurrence and PE-related mortality but increases bleeding risk, without improving overall survival or net clinical benefit over 6 months.

Prev
2 / 2
12
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities